Constarium
← Search

Table · dataset · 2026

Supplementary file 1_Preclinical characterization of S095029, a novel clinical-stage Fc-attenuated NKG2A-blocking antibody for cancer immunotherapy.docx

Listed in figshare and Loughborough Research Repository — shown once because both records carry DOI 10.3389/fonc.2026.1924010.s001

<p>Natural killer group 2 family of receptor A (NKG2A) and its ligand human leukocyte antigen-E (HLA-E) are increasingly recognised as an important immune checkpoint restraining lymphocyte populations involved in cancer immunity.

Description

Recent clinical studies investigating dual NKG2A/programmed death ligand 1 (PD-L1) blockade versus anti-PD-L1 monotherapy suggest that the combination may be beneficial in immunotherapy-responsive disease settings.

To date, clinical safety and efficacy results are only available for a single NKG2A-blocking monoclonal antibody (mAb). Here, we report on the generation and preclinical characterization of a novel NKG2A-blocking agent. The fully human Fc-attenuated immunoglobulin G1 mAb S095029, selected via functional antibody repertoire screening, was tested against benchmark clinical-stage antibodies in in vitro binding and functional NKG2A/HLA-E blockade assays.

Read the rest (2 more)

S095029 bound human NKG2A with a low nanomolar-range affinity and efficiently reversed the inhibitory effects of NKG2A/HLA-E interaction. As a single agent, S095029 enhanced the activation, cytotoxicity, and cytokine secretion of natural killer (NK) and γδ T cells. S095029 improved NK cell antibody-dependent cellular cytotoxicity and other effector functions triggered by Fc-competent mAbs.

In vivo investigations in syngeneic mouse models showed that S095029 inhibited tumour growth by harnessing the anti-tumour activity of both NK and CD8+ T cells. Overall, our results support the clinical development of S095029 in immuno-oncology-responsive tumour settings with adequate HLA-E expression. Phase 1b/2 dose escalation studies are currently underway to evaluate S095029 in combination with anti-PD-1 in non-small cell lung cancer and gastric cancer.</p>

Links

Where it is published

Catalogue records · 1

Topics

Inferred from text
Cancer 75% · Disease 75% · Oncology and carcinogenesis 70%
Provenance · 2 source records, 31 field assertions
SourceKeyLast seenRaw
figshareoai:figshare.com:article/339729799 d agoJSON v1
Loughborough Research Repositoryoai:figshare.com:article/339729799 d agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · figshare comconnector:figshare_com@1.0.0
concepts[disease].local:disease:cancerenrichment · figshare comkeyword-concept-rules@1.0.0title+description (75%)
concepts[disease].local:disease:diseaseenrichment · figshare comkeyword-concept-rules@1.0.0title+description (75%)
concepts[field].anzsrc:group:3211enrichment · figshare comtaxonomy-embedding@1.0.0title+keywords+description (70%)
concepts[field].local:field:astronomymapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:chemistrymapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:chemistrymapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:computer-science-aimapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:computer-science-aimapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:earth-environmentalmapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:earth-environmentalmapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:economics-financemapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:economics-financemapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:engineeringmapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:engineeringmapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:humanitiesmapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:humanitiesmapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:life-sciencesmapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:life-sciencesmapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:materials-sciencemapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:mathematics-statisticsmapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:medicine-healthmapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:medicine-healthmapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:ocean-atmosphericmapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:psychology-behavioralmapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
concepts[field].local:field:social-sciencemapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:social-sciencemapping · repository lboro ac ukconnector:repository_lboro_ac_uk@1.0.0
descriptionsource · figshare comconnector:figshare_com@1.0.0/metadata/dc/description
licensesource · figshare comconnector:figshare_com@1.0.0/metadata/dc/rights
publication_datesource · figshare comconnector:figshare_com@1.0.0
titlesource · figshare comconnector:figshare_com@1.0.0/metadata/dc/title